University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Bhairavi Tolani, PhD

Bhairavi Tolani, PhD

Assistant Professor, Dept. of Surgery, UCSF

Cancer Center Program Memberships

Experimental Therapeutics

Education

Hood College B.A. 2001-2004 Biochemistry
Hood College and National Cancer Institute (thesis), M.S., 2005-2007, Biomedical Sciences
University of Southern California, Ph.D., 2007-2013, Molecular Biology
Stanford Research Institute, Postdoc, 2013-2014, Cancer Immunology
University of California, San Francisco, Postdoc, 2014-2015, Translational Oncology


Professional Experience

  • 2004 – 2005
    Technician - DNA Manufacturer, Custom Primers, Invitrogen Life Technologies
  • 2005 – 2006
    Operations Technician, Clonetics/Cell Therapy, Cambrex BioScience (Lonza Corporation) 
  • 2006 – 2007
    Scientific Associate II, Research and Development Dept., Digene Corporation (Qiagen) 
  • 2007 – 2013
    Graduate Research Assistant, Molecular and Computational Biology, Hematology/Oncology, Keck School of Medicine, University of Southern California 
  • 2013 – 2014
    Postdoctoral Fellow, Cancer Immunology, Bioscience Division, Stanford Research Institute 
  • 2014 – 2015
    Postdoctoral Fellow, Thoracic Oncology Laboratory, Department of Surgery, Helen Diller Comprehensive Cancer Center, UCSF
  • 2015 – present
    Assistant Adjunct Professor, Thoracic Oncology Laboratory, Department of Surgery, Helen Diller Comprehensive Cancer Center, UCSF

Honors & Awards

  • 2004
    "Outstanding Poster Presentation" Spring Research Festival, National Cancer Institute
  • 2004
    Job Excellence, Invitrogen Life Technologies
  • 2005
    “No Matter What it Takes”, Cambrex BioScience (Lonza)
  • 2010
    "Best Poster" at Biology Interdept. Grad Symposium, University of Southern California
  • 2014
    Keller Entrepreneurship Fellow, University of California, Davis

Selected Publications

  1. Chang Y, Tolani B, Nie X, Zhi X, Hu M, He B. Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring. Ther Clin Risk Manag. 2017; 13:1363-1374.
    View on PubMed
  2. Giroux-Leprieur E, Tolani B, Li H, Leguay F, Hoang NT, Acevedo LA, Jin JQ,Tseng HH, Hue D, Kim IJ, Wislez M, Wang C, Jablons D, He B. . Membrane-bound full-length Sonic Hedgehog identifies cancer stem cells in human non-small cell lung cancer. Oncotarget. 2017.
    View on PubMed
  3. Li H, Yue D, Jin JQ, Woodard GA, Tolani B, Luh TM, Giroux-Leprieur E, Mo M, Chen Z, Che J, Zhang Z, Zhou Y, Wang L, Hao X, Jablons D, Wang C, He B. Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas. Oncotarget. 2016 Dec 06; 7(49):80415-80425.
    View on PubMed
  4. Yue D, Li H, Che J, Zhang Y, Tolani B, Mo M, Zhang H, Zheng Q, Yang Y, Cheng R, Jin JQ, Luh TW, Yang C, Tseng HH, Giroux-Leprieur E, Woodard GA, Hao X, Wang C, Jablons DM, He B. EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas. PLoS One. 2015; 10(7):e0132134.
    View on PubMed
  5. Gopalakrishnan R, Matta H, Tolani B, Triche T, Chaudhary PM. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene. 2016 Apr 07; 35(14):1797-810.
    View on PubMed
  6. Mo ML, Ma J, Chen Z, Wei B, Li H, Zhou Y, Shi H, Tolani B, Jin JQ, Tseng HH, Shen D, Zhan Y, Li J, Jablons DM, Zhang RQ, Guo Y, He B, Zhou HM. Measurement of genome-wide DNA methylation predicts survival benefits from chemotherapy in non-small cell lung cancer. J Cancer Res Clin Oncol. 2015 May; 141(5):901-8.
    View on PubMed
  7. Tolani B, Matta H, Gopalakrishnan R, Punj V, Chaudhary PM. NEMO is essential for Kaposi's sarcoma-associated herpesvirus-encoded vFLIP K13-induced gene expression and protection against death receptor-induced cell death, and its N-terminal 251 residues are sufficient for this process. J Virol. 2014 Jun; 88(11):6345-54.
    View on PubMed
  8. Tolani B, Gopalakrishnan R, Punj V, Matta H, Chaudhary PM. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene. 2014 May 29; 33(22):2928-37.
    View on PubMed
  9. Graham C, Matta H, Yang Y, Yi H, Suo Y, Tolani B, Chaudhary PM. Kaposi's sarcoma-associated herpesvirus oncoprotein K13 protects against B cell receptor-induced growth arrest and apoptosis through NF-?B activation. J Virol. 2013 Feb; 87(4):2242-52.
    View on PubMed
  10. Matta H, Gopalakrishnan R, Graham C, Tolani B, Khanna A, Yi H, Suo Y, Chaudhary PM. Kaposi's sarcoma associated herpesvirus encoded viral FLICE inhibitory protein K13 activates NF-?B pathway independent of TRAF6, TAK1 and LUBAC. PLoS One. 2012; 7(5):e36601.
    View on PubMed

Go to UCSF Profiles, powered by CTSI